cbdc benefits Top stories

Yiling Pharmaceutical Co., Ltd.: The application for clinical trial of Lianhua Yuping Granule was approved, and Yiling Pharmaceutical announced that Beijing Yiling, a wholly-owned subsidiary, received the Notice of Approval for Clinical Trial of Drugs approved and issued by National Medical Products Administration on December 12, 2024, and agreed to carry out clinical trial of Lianhua Yuping Granule for qi deficiency syndrome of common cold.Market news: Israel said that the IDF will stay on the Syrian side of Mount Hermon for several months.Institutions: The prospect of sanctions has caused supply concerns, and oil prices are bound to record an increase in Zhou Du and an increase in Zhou Du. The prospect of more severe sanctions on Russian and Iranian countries has caused market concerns about supply disruption. US Treasury Secretary Yellen said that the United States is looking for ways to curb Russia's income, and Trump's national security candidate vowed to put the greatest pressure on Iran. These two factors boosted the benchmark oil price by 3% to 4% this week. In addition, political turmoil in the Middle East and other factors have also provided support for oil prices. However, the International Energy Agency (IEA) said yesterday that the global market will still face oversupply next year.

Yiling Pharmaceutical Co., Ltd.: The application for clinical trial of Lianhua Yuping Granule was approved, and Yiling Pharmaceutical announced that Beijing Yiling, a wholly-owned subsidiary, received the Notice of Approval for Clinical Trial of Drugs approved and issued by National Medical Products Administration on December 12, 2024, and agreed to carry out clinical trial of Lianhua Yuping Granule for qi deficiency syndrome of common cold.Tianyu Co., Ltd.: The subsidiary company plans to select the tenth batch of national centralized drug procurement, and the wholly-owned subsidiary company Zhejiang Nuode Pharmaceutical Co., Ltd. plans to select the product of sitagliptin metformin tablets (II) and sitagliptin phosphate tablets to select the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office.Gao Xiuying, the former deputy general manager of CITIC Daika Co., Ltd., was "double-opened". After investigation, Gao Xiuying, as a leading cadre of party member, a state-owned enterprise, abandoned his initial mission and deliberately opposed organizational review, taking the lead in breaking the discipline and breaking the law, seriously polluting the political ecology of his unit; Ignoring the spirit of the eight central regulations, illegally accepting gifts, banquets and travel arrangements; Violation of organizational principles, failure to report personal matters truthfully, running away from official positions, and making profits for relatives and friends in employee recruitment and job transfer; There is no bottom line for honesty, illegally holding shares of non-listed companies, and wantonly engaging in illegal business operations abroad to obtain huge profits; Failing to report and submit working materials to the superior unit as required; Moral corruption, violation of life discipline. Rely on enterprises to eat enterprises, harm the public and enrich the private interests, use their powers to ask for property from subordinates, illegally operate the same business of the enterprises they serve, and seek huge illegal interests.

Borui Medicine: Carboprost injection is planned to win the bid for the national centralized drug procurement. Borui Medicine announced that in the tenth batch of national centralized drug procurement in which Borui Pharmaceutical, a wholly-owned subsidiary, participated, carboprost tromethamine injection is planned to win the bid. This product is mainly used for 13-20 weeks pregnant abortion and postpartum hemorrhage. The specification is 1 ml: 250μ g, and the proposed bid price is 16.96 yuan/piece. In the first year, the agreed purchase base is 220,400 pieces, which are mainly supplied to Henan, Hubei, Guangxi, Shaanxi, Gansu, Ningxia and other provinces. If the contract is finally selected and signed, it will help the product to quickly open the domestic market and enhance the market share and brand influence of the company. The product obtained the drug registration certificate in March 2024, and has not yet generated sales revenue.Bank of Communications: Wang Wenjin resigned as business director. Due to job transfer, Wang Wenjin has submitted a written report to the board of directors of the company and resigned as business director (corporate and institutional business). His resignation will take effect on December 13, 2024.Huifa Food: Shareholder Zhenghechang Investment Co., Ltd.' s shareholding reduction plan has not been completed yet, and Huifa Food announced the change. On November 8, 2024, the company disclosed the Announcement of Huifa Food Shareholder's shareholding reduction plan, and Shareholder Zhenghechang Investment Co., Ltd. plans to reduce its shareholding by centralized bidding to no more than 2,446,423 shares, which does not exceed 1% of the company's total share capital; The reduction of holdings through block trading does not exceed 4,892,846 shares, and does not exceed 2% of the company's total share capital. The planned reduction period is from November 29, 2024 to February 27, 2025. As of December 13, 2024, shareholder Zhenghechang Investment Co., Ltd. has reduced its shareholding by 1.7 million shares through centralized bidding. At present, the shareholder's shareholding reduction plan has not been completed.